Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

YourVaccx, a new type of cancer vaccine developed by ImmunSYS, is safe and shows promising effectiveness in patients with metastatic prostate cancer and other difficult-to-treat advanced solid tumors, a proof-of-concept study shows.

Study findings were presented in a poster titled, “Regression of metastatic cancer and abscopal effects following in situ vaccination by cryosurgical tumor cell lysis and intratumoral immunotherapy: A case series,” at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II, June 22-24. YourVaccx uses a proprietary procedure developed by ImmunSYS that is designed to boost the activity of the immune system to fight cancer. The therapy comprises two steps. First, a portion of the tumor is destroyed using a technique called local cryosurgical tumor cell lysis (disintegration), so that molecules found within the tumor are released to the exterior. These molecules will activate and instruct patients’ immune cells to attack the tumor. A combination of three immunotherapy agents then are injected into the disrupted tumor, which is intended to block inhibitory signals from cancer cells that prevent the immune system from acting and to promote the proliferation of immune cells and their migration into c
Subscribe or to access all post and page content.